| Year |
Citation |
Score |
| 2022 |
Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner EE, Scherzer MT, Schuman S, van Veen JE, Murphy B, Hackett CS, Dupuy AJ, Chmura SA, van der Weyden L, Newberg JY, Liu A, et al. Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. Cancer Research. PMID 36112789 DOI: 10.1158/0008-5472.CAN-21-3214 |
0.526 |
|
| 2015 |
Chen J, Hackett CS, Zhang S, Song YK, Bell RJ, Molinaro AM, Quigley DA, Balmain A, Song JS, Costello JF, Gustafson WC, Van Dyke T, Kwok PY, Khan J, Weiss WA. The genetics of splicing in neuroblastoma. Cancer Discovery. 5: 380-95. PMID 25637275 DOI: 10.1158/2159-8290.Cd-14-0892 |
0.758 |
|
| 2014 |
Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, et al. Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. Cell Reports. 9: 1034-46. PMID 25437558 DOI: 10.1016/J.Celrep.2014.09.046 |
0.762 |
|
| 2014 |
Chen J, Hackett CS, Zhang S, Song YK, Molinaro A, Quigley DA, Balmain A, Gustafson WC, Dyke TAV, Kwok P, Khan J, Weiss WA. Abstract 3413: A genetic analysis of splicing in neuroblastoma identifies opposing functions for FUBP1 splice variants in MYC regulation Cancer Research. 74: 3413-3413. DOI: 10.1158/1538-7445.Am2014-3413 |
0.759 |
|
| 2013 |
Diede SJ, Yao Z, Keyes CC, Tyler AE, Dey J, Hackett CS, Elsaesser K, Kemp CJ, Neiman PE, Weiss WA, Olson JM, Tapscott SJ. Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics : Official Journal of the Dna Methylation Society. 8: 1254-60. PMID 24107773 DOI: 10.4161/Epi.26486 |
0.512 |
|
| 2012 |
Huang X, Dubuc AM, Hashizume R, Berg J, He Y, Wang J, Chiang C, Cooper MK, Northcott PA, Taylor MD, Barnes MJ, Tihan T, Chen J, Hackett CS, Weiss WA, et al. Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes & Development. 26: 1780-96. PMID 22855790 DOI: 10.1101/Gad.193789.112 |
0.733 |
|
| 2012 |
Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 21: 601-13. PMID 22624711 DOI: 10.1016/J.Ccr.2012.04.012 |
0.7 |
|
| 2012 |
Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Science Translational Medicine. 4: 115ra3. PMID 22218692 DOI: 10.1126/scitranslmed.3002977 |
0.732 |
|
| 2010 |
Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Science Signaling. 3: ra81. PMID 21062993 DOI: 10.1126/Scisignal.2001017 |
0.673 |
|
| 2010 |
Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, ... Hackett CS, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nature Medicine. 16: 1134-40. PMID 20871609 DOI: 10.1038/Nm.2227 |
0.741 |
|
| 2010 |
Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, et al. Pleiotropic role for MYCN in medulloblastoma. Genes & Development. 24: 1059-72. PMID 20478998 DOI: 10.1101/Gad.1907510 |
0.754 |
|
| 2009 |
Hackett CS, Weiss WA. A translational end-run for a rare, genetically enigmatic tumor. Cancer Biology & Therapy. 8: 2396-7. PMID 20009571 DOI: 10.4161/Cbt.8.24.10507 |
0.517 |
|
| 2009 |
Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Diers MD, Rodriguez FJ, Bender AM, Tieu C, Matise I, Dupuy AJ, Copeland NG, Jenkins NA, Hodgson JG, et al. Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Research. 69: 8429-37. PMID 19843846 DOI: 10.1158/0008-5472.Can-09-1760 |
0.579 |
|
| 2007 |
Hackett CS, Geurts AM, Hackett PB. Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy. Genome Biology. 8: S12. PMID 18047689 DOI: 10.1186/Gb-2007-8-S1-S12 |
0.318 |
|
| 2007 |
Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Research. 67: 7960-5. PMID 17804702 DOI: 10.1158/0008-5472.Can-07-2154 |
0.658 |
|
| 2007 |
Cheng AJ, Cheng NC, Ford J, Smith J, Murray JE, Flemming C, Lastowska M, Jackson MS, Hackett CS, Weiss WA, Marshall GM, Kees UR, Norris MD, Haber M. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 43: 1467-75. PMID 17449239 DOI: 10.1016/J.Ejca.2007.03.008 |
0.515 |
|
| 2003 |
Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Research. 63: 5266-73. PMID 14500357 |
0.564 |
|
| 2003 |
Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, Kuriyama N, Milshteyn N, Roberts T, Wendland MF, DePinho R, Israel MA. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Research. 63: 1589-95. PMID 12670909 |
0.597 |
|
| Show low-probability matches. |